Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CN-I LIVER THERAPY

Financiado

Cerrado

POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS FOR THE TREATMENT OF CRIGLER NAJJAR...

POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS FOR THE TREATMENT OF CRIGLER NAJJAR LIVER DISEASE A PRECLINICAL SAFETY ASSESSMENT Currently, the only cure for many inherited metabolic liver diseases with severe extra-hepatic manifestations, such as Crigler-Najjar disease (CNI), is liver transplantation (LT). LT goes together with heavy surgery, life-long imm... ver más

31/10/2016

UNIGE

199K€

Presupuesto del proyecto: 199K€

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-10-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIGE

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ENHANCE Engineering the 3D Niche to enHANCE functionality of hepatoc... 183K€ Cerrado

relieve-IMDs Reprogramming cell identity to develop new therapies against... 2M€ Cerrado

InnovaLiv Innovative strategies to generate human hepatocytes for trea... 8M€ Cerrado

CELLNAIVETY Deciphering the Molecular Foundations and Functional Compete... 2M€ Cerrado

i-THYMUS The i-Thymus: wielding the potential of gene therapy, cell t... 4M€ Cerrado

EASY-IPS a rapid and efficient method for generation of iPSC 150K€ Cerrado

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 199K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently, the only cure for many inherited metabolic liver diseases with severe extra-hepatic manifestations, such as Crigler-Najjar disease (CNI), is liver transplantation (LT). LT goes together with heavy surgery, life-long immunosuppression and important public health costs. Development of less invasive treatments will permit important benefits for the patients and economic savings. Combination of gene therapy and hepatocyte (HEP) transplantation is a promising alternative to LT, correcting the metabolic defect while keeping in place the normal native liver. Nevertheless, the major obstacle has been shown to be the insufficient amount of corrected HEP available for transplantation. Induced pluripotent stem cells (iPS) are endowed with intrinsic self-renewal ability and the potential to differentiate into any of the three germ layers allowing cell amplification before differentiation. As such, iPS are heralded as the most promising avenue for cell-based therapeutics. However, recent evidences indicate that the epigenetic features of iPS are heterogeneous and notably influenced by the tissue of origin of the reprogrammed cells. Hypothesis: HEP reprogramming and differentiation induce profound epigenetic changes that could affect the safety of gene and stem cell therapy combination approach. Objectives: 1) Reprogramming of patient-specific CNI-HEP into iPS. 2) Correction of CNI-iPS by ex vivo lentiviral transduction. 3) Large-scale amplification of the corrected CNI-iPS and differentiation to HEP-like cells. 4) Epigenetic analysis of patient CNI-HEP, CN-iPS and the differentiated-corrected cells. 5) Therapeutic assessment of corrected CN-HEP-like cells into the liver of the CNI animal model. This project will allow a step forward to studying the safety, efficacy and clinical potential of differentiated cells derived from patient-specific iPS. Importantly, not only CNI disease but also many other inborn liver disorders are potentially treatable via this approach.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores